SARS-CoV-2 has been shown to down-regulate the angiotensin-converting enzyme 2 (ACE2) protein [15], which might explain why COVID-19 patients with diabetes and cardiovascular disease had poorer clinical outcomes. This evidence concerns the gene ACE2 and COVID-19.